FDA grants priority review to TB drug
FDA has granted priority review to bedaquiline, or TMC207 (Johnson & Johnson's Janssen Research & Development), for treatment of multidrug-resistant tuberculosis.
FDA has granted priority review to bedaquiline, or TMC207 (Johnson & Johnson's Janssen Research & Development), for treatment of multidrug-resistant tuberculosis (TB). Bedaquiline would be the first drug specifically indicated for multidrug-resistant TB, and the first new type of TB drug in more than 4 decades.
On June 29, the drug maker applied for approval to market bedaquiline as part of combination therapy for adults with multidrug-resistant TB lung infections.
Under a priority review, FDA aims to decide whether to approve drugs within 6 months of the application's submission, rather than the standard 10 months.
About 1.4 million people worldwide die from TB each year, about 10% of them from forms resistant to at least two of the standard drugs for the deadly bacterial disease.
J&J applied for approval to market the drug in the European Union on Aug. 31.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
